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Icatibant is not helpful for the treatment of 
ACE inhibitor-induced angioedema 
SAMANTHA R. SCHWARTZ, B.S., M.S., Wayne State University School of Medicine, saschwar@med.wayne.edu 
 
ABSTRACT A critical appraisal and clinical application of Sinert R, Levy P, Bernstein JA, et al. Randomized trial of icatibant for 
angiotensin-converting enzyme inhibitor-induced upper airway angioedema. J Allergy Clin Immunol Pract. 2017; 5(5): 1402-1409. 
doi: 10.1016/j.jaip.2017.03.003. 
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Clinical Context 
A 67-year-old African American woman, with a relevant past medical history of chronic obstructive pulmonary 
disease and hypertension, presented to the general practice unit (GPU) following a one day course in the medical 
intensive care unit (MICU) for angiotensin inhibitor-induced angioedema (ACE I-induced angioedema). The patient 
initially presented to the emergency department (ED) with a 3 day history of progressive facial swelling after 
initiating lisinopril therapy six days prior. Originally periorbital, the swelling gradually increased in severity to 
include her mouth and throat eliciting vocal changes. Serial arterial blood gases in the ED demonstrated 
hypercapnic respiratory failure with persistent respiratory acidosis requiring intubation. The patient was 
transferred to the MICU, stabilized, and was extubated in <24 hours. On admission to the GPU the patient stated, 
“It scares me that I had to be intubated. Was there any therapy that could have prevented this from happening?” 
Clinical Question 
Is there a medical therapy targeting ACE-I induced angioedema, manifesting due to elevated levels of bradykinin, that decreases the 
severity of the disease process and manifestation? 
Research Article 
Sinert R, Levy P, Bernstein JA, et al. Randomized trial of icatibant for angiotensin-converting enzyme inhibitor-induced upper airway 
angioedema. J Allergy Clin Immunol Pract. 2017; 5(5): 1402-1409. doi: 10.1016/j.jaip.2017.03.003 
Related Literature 
ACE I-induced angioedema occurs in up to 0.68% of patients taking ACE inhibitors with up to a 4.5-fold higher rate of diagnosis in 
African Americans.1-4 It accounts for 30% of all emergency room visits for angioedema and has increasing prevalence due to the 
widespread administration of ACE inhibitors.5,6 The current management of ACE I-induced angioedema includes symptomatic control 
with glucocorticoids and antihistamines. At this time there is no approved treatment for this potentially life-threatening condition. 
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PubMed database was utilized to perform a literature review for articles including the search terms “((Icatibant[Title/Abstract]) AND 
angioedema[Title/Abstract]) AND ACE inhibitor[Title/Abstract]", and the results were reviewed. An article by Bas et al. was on topic, 
and the search results were further explored using the “Similar Articles” feature resulting in 104 titles whose abstracts were 
reviewed for relevance. Three were selected for further analysis.  
A multicenter, double-blind, double-dummy, randomized phase 2 clinical trial published in 2015 in the New England Journal of 
Medicine by Bas et al. found that the use of subcutaneous icatibant for the treatment of ACE I-induced angioedema led to 
significantly faster onset of symptom relief and complete resolution of symptoms in 70% less time compared to standard 
treatment.7 One concern in regard to this study is the small sample size. Only 27 patients were included, which limits the ability to 
generalize the conclusions to the public.8 In addition one needs to be wary of the possibility of funding bias as the pharmaceutical 
company Shire, the manufacturer of icatibant, provided funding for the study. Lastly, the study was performed in Germany limiting 
the applicability to our patient. All study participants were white with only 3 of 27 taking lisinopril.7 In addition to the race 
distribution not being representative of the United States population, African Americans are known to suffer from a more severe 
form of ACE I-induced angioedema.3,4  
Of note, a double-blind placebo-controlled randomized study published in 2017 in the Journal of Allergy and Clinical Immunology by 
Straka et al. was terminated following the publication by Bas et al. with findings discordant to the prior study. Straka et al. provided 
statistical analysis of data collected prior to study discontinuation. Similarities to the study by Bas et al. include a small sample size of 
33 participants and concern for funding bias due to partial funding by Shire Pharmaceuticals.9 However, of importance, a greater 
number of patients identified as black and female and administered lisinopril, versus alternative types of ACE inhibitors, prior to 
presentation. 9 
The article chosen for the critical appraisal is a phase 3, 2-armed, double-blind randomized clinical trial published in 2017 in the 
Journal of Immunology and Clinical Pharmacology by Sinert et al. with findings that dispute those of Bas et al. This article found that 
icatibant did not provide a statistically significant benefit in the treatment of ACE I-induced angioedema compared to placebo.10 The 
study by Sinert et al. addresses many of the concerns regarding the applicability of the study by Bas et al. including: a larger sample 
size of 121 subjects, 69.4% of participants identifying as black or African American, and lisinopril as the most frequently taken ACE 
inhibitor.10 Our patient met all but one of inclusion criteria of this study. 
Critical Appraisal 
Sinert et al. conducted a phase 3, 2-armed, double-blind randomized clinical trial at 31 of 59 centers in the United States, United 
Kingdom, Israel, and Canada from December 2013 through August 2015.10 The purpose of the study was to determine the efficacy of 
icatibant as a treatment for ACE I-induced angioedema of at least moderate severity. As a multicenter randomized control trial, the 
strength of the study is level 1 based on SORT criteria.11 
Study participants were enrolled if they met the following criteria: aged 18 years or older, presenting with at least moderate severity 
ACE-I angioedema that manifested in the last 12 hours, and did not have a diagnosis, personal history, or family history of other 
types of angioedema. A blinded physician assessing 4 clinical domains determined the episode severity. These domains were 
difficulty breathing, difficulty swallowing, voice changes, and tongue swelling and were measured with a severity rating of 0 to 4. 
Once enrolled, study participants were randomly assigned to the icatibant group or the placebo group in a 1:1 ratio. All subjects 
received a single 3 mL subcutaneous injection of 30 mg icatibant or an isotonic acetate-buffered solution. A physician measured the 
severity of the 4 symptoms at baseline, 30 minutes, 1 hour, and hourly up to 8 hours following drug administration. Severity 
continued to be measured every 2 hours until 24 hours and every 3 hours from that point on if the primary end point of the study 
was not met. 
The primary efficacy end point of the study was time to meeting discharge criteria. Discharge criteria was defined as the earliest 
time following study drug administration that difficulty breathing and swallowing were absent and voice changes and tongue 
swelling were mild or absent. Secondary outcomes included time to onset of symptom relief, occurrence of airway intervention, and 
admission to the hospital. 
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The analysis was performed using an intention-to-treat analysis, which led to a total of 121 patients. Sinert et al. demonstrated that 
there were no statistically significant differences in the primary efficacy end point and the secondary end points of the study. In both 
study groups, median time to meet discharge criteria was 4.0 hours (p = 0.68). The median time to onset of symptom relief was 2.0 
hours in the icatibant group and 1.6 in the placebo group (p = 0.57). The results of this study are not consistent with the study 
performed by Bas et al. 
Strengths of the study include a large sample size. The study investigators determined that a sample size of at least 100 would result 
in a 95% power to detect a difference in the primary efficacy end point using Kaplan-Meier estimates. In addition, evidence was 
provided demonstrating that both the care team and subjects were blinded to the study treatment administered. 
There are several limitations to the study as well. Potential confounding factors are present as participant treatment was not 
confined to study drug administration. 90% of subjects were administered corticosteroids, antihistamines, and epinephrine prior to 
study drug administration. 45% of subjects were administered antihistamines following study drug administration. Therefore, study 
participants were receiving the current standard of care with concurrent study drug administration. In addition, the median time for 
administration of the study drug was 7.8 hours. The delay in administration may have led to the exclusion of eligible study 
candidates who were rapidly decompensating. A limitation of the exclusion criteria exists as it was not specified if patients had 
previous episodes of ACE I-induced angioedema. Successive exacerbations are known to increase in both frequency and severity.12 
Of critical importance, the patient of interest did not align with all aspects of the study by Sinert et al. She met all of the inclusion 
criteria with the exception of experiencing symptoms for greater than 12 hours. Her age, race, and use of lisinopril correlated with 
baseline characteristics. However, other factors in regard to her care were not appropriately addressed including her history of 
pulmonary disease, use of multiple hypertension medications, and the small sample size of subjects requiring a MICU stay.  
Of additional concern is the possibility of funding bias as Shire, the manufacturer of icatibant, funded the study. However, the results 
of the study do not support the use of Shire’s product. In addition, employees of Shire were not involved in the interpretation of 
data or the decision to publish the results. 
Clinical Application 
Current clinical practice utilizes the administration of glucocorticoids and antihistamines for symptomatic relief of 
ACE I-induced angioedema. The treatment protocol does not endorse the use of icatibant at this time. Bas et al. 
and Sinert et al. provide conflicting recommendations that complicate the overall picture and understanding of the 
impact of icatibant on patient care. Based on the findings of the larger, more comprehensive Sinert trial, which 
showed no improvement in time to discharge or symptom relief over placebo, it is unlikely that treatment with 
icatibant would have improved this patient’s outcome or prevented her from being intubated. 
Learning points: 
1. Although rare, ACE I-induced angioedema accounts for 30% of all emergency room visits for angioedema. 
2. Icatibant offers no reduction in time to discharge or resolution of symptoms of angioedema compared to 
placebo. 
3. Currently there is no appropriate treatment regimen to address the mechanism of ACE I-induced angioedema. 
Management provides symptomatic relief with glucocorticoids and antihistamines. 
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